News

Glycostem listed in independent article

November 2016;

Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.

Read more >

NK 2016 16th Meeting of Society for Natural Immunity

October 2-5, 2016
Glycostem presented their recent advances in NK cell therapy for hematological and solid cancers at NK 2016.

Read more >

Annual Discovery on Target Event, Boston

September 19-22, 2016
Glycostem's CSO, Dr. Jan Spanholtz, has been invited as speaker at the 14th Annual Discovery on Target Event, Boston, USA

CTIP Conference Hamburg

June 27-28, 2016
Dr. Jan Spanholtz (CSO) presents at the 5th Clinical Trials Innovation Programme Conference (CTIP), Hamburg, Germany

BIO International Convention San Francisco

June 6-9, 2016
Dr. Wim Jongen (CEO) represents Glycostem at the BIO International Convention in San Francisco, USA

Health Valley Event, Pivot Park Oss

June 2, 2016
Dr. Jan Spanholtz (CSO) gives a presentation on Innovative Cellular Medicine at the Health Valley Event Exit Oss: 'Crossing Borders', Pivot Park, Oss, The Netherlands

Innate Killer Summit

May 16-18, 2016
Dr. Jan Spanholtz (CSO) presents results of clinical phase I study at the Innate Killer Summit, San Diego, USA

Orphan-Drug Designation request of NK Cell Product oNKord® granted by FDA

April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)

Adopt Summit

March 1-3, 2016
Glycostem's CSO, Dr. Jan Spanholtz presents clinical phase I data at the Adopt Summit 2016: Adoptive Immunotherapy, London, UK

Biotech Showcase San Francisco

Jan 11-13, 2016
Glycostem will be represented at Biotech Showcase, the 8th Annual Biotechnology Investor and Partnering Conference, San Francisco, USA.

Wim Jongen (CEO) and Jan Spanholtz (CFO) will participate.

ASH Annual Meeting

December 4-8, 2015

Glycostem together with Radboud University Medical Center presents results of their Phase I clinical trial in AML patients at the 57th ASH Annual Meeting, Orlando, USA

Poster presentation by Dr. Harry Dolstra and Dr. Jan Spanholtz

Read more >

Bio-Europe

November 2-4, 2015

Glycostem's CEO, Dr. Wim Jongen, gives a company presentation at Bio-Europe, Munich, Germany

Natural Killer Cell Symposium

October 7-9, 2016
Dr. Jan Spanholtz and John Veluchamy attend the Natural Killer Cell Symposium, Göttingen, Germany. John Veluchamy (PhD fellow) will present a poster at this meeting.

Sachs Forum

September 29-30, 2015

Glycostem's CEO, Dr. Wim Jongen, gives a company presentation at 15th Annual Biotech in Europe Forum, Basel, Switzerland

Health Valley Event, Pivot Park Oss

July 9, 2015

Glycostem's CSO, Dr. Jan Spanholtz, gives a presentation on Cell Therapy in Oncology at the Health Valley Event Exit Oss, Pivot Park, Oss, The Netherlands

Read more >

NK2015

May 2-6, 2015

Glycostem's CSO, Dr. Jan Spanholtz, presents Poster at NK2015, 15th Annual Meeting of the Society for Natural Immunity, Montebello, Québec, Canada

Read more >

Glycostem launches its new website

On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.

Read more >